ConductScience.org, home

Comparison · NCT00326612-dedf6347

Intranasal Midazolam vs Rectal Diazepam: Number of Patients Who Needed Additional Medication to Treat the Seizure in the Emergency Department Within 24 Hours

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Intranasal Midazolam vs Rectal Diazepam: Number of Patients Who Needed Additional Medication to Treat the Seizure in the Emergency Department Within 24 Hours. Trial comparisons, record NCT00326612-dedf6347. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00326612-dedf6347

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.10.04350.214wilson
Risk in group 20.1190.05190.25wilson
Risk difference, group 1 minus group 2-0.019-0.1620.113newcombe hybrid score
Risk ratio, group 1 over group 20.840.2612.71log
Odds ratio, group 1 over group 20.8220.2213.06log
Number needed to treat, for one fewer participant with the outcome on Intranasal Midazolam than on Rectal Diazepam52.5from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Intranasal Midazolam0.2 mg/kg Intranasal Midazolam for a seizure longer than 5 minutes550OG000
Group 2Rectal Diazepam0.3-0.5 Rectal Diazepam for a seizure lasting longer than 5 minutes542OG001

Outcome

Type
SECONDARY
Title
Number of Patients Who Needed Additional Medication to Treat the Seizure in the Emergency Department Within 24 Hours
Description
Time frame
24 hours
Population

Source ClinicalTrials.gov

Trial

Title
Intranasal Midazolam Versus Rectal Diazepam for Treatment of Seizures
NCT number
NCT00326612
Phases
PHASE2
Conditions
Seizures
Interventions
Midazolam, Diazepam
Lead sponsor
University of Utah
Results first posted
2011-10-26

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT00326612-dedf6347